Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Non–ST-Segment–Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease: Results From the Evaluation of Drug-Eluting Stents and Ischemic Events Registry
暂无分享,去创建一个
M. Pencina | S. Bangalore | N. Kleiman | D. Cohen | D. Cohen | D. Cohen
[1] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[2] Harlan M Krumholz,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[3] M. Pencina,et al. Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: Results From a Propensity Score–Matched Analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry , 2011, Circulation. Cardiovascular interventions.
[4] A. Kastrati,et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. , 2008, The New England journal of medicine.
[5] B. Gersh,et al. Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.
[6] A. Kastrati,et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. , 2008, Journal of the American College of Cardiology.
[7] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[8] H. White,et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. , 2007, Journal of the American College of Cardiology.
[9] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[10] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[11] E. Braunwald,et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. , 2006, Journal of the American College of Cardiology.
[12] M. Gheorghiade,et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. , 2006, European heart journal.
[13] R. Califf,et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.
[14] David J Cohen,et al. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. , 2005, American heart journal.
[15] E. Topol,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.
[16] D. Rubin. Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation , 2001, Health Services and Outcomes Research Methodology.
[17] P D Cleary,et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. , 2001, Journal of clinical epidemiology.
[18] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[19] E. Topol,et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. , 2004, Journal of the American College of Cardiology.
[20] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi , 2004, The Canadian journal of cardiology.